Barb only please

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

JUL - 9 2002

Requester's Full Name: Dwayne Jones Examiner #: 71299 Date: 09JUL02

Art Unit: 1614 Phone Number 30 8-4634 Serial Number: 09/955,016

Mail Box and Bldg/Room Location: 2007 CM1 Results Format Preferred (circle): PAPER DISK E-MAIL

2007, CM1

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names): "

"

Earliest Priority Filing Date: "

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search claims 1, 2 and 14

RECEIVED JUL - 9 2002 (STIC)

BEST AVAILABLE COPY

Point of Contact:
Barb O'Bryen
Technical Information Specialist
STIC CM1 6A05 308-4291

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher: BOB	NA Sequence (#)		STN	173
Searcher Phone #:	AA Sequence (#)		Dialog	30
Searcher Location:	Structure (#)		Questel/Orbit	
Date Searcher Picked Up:	Bibliographic	8	Dr.Link	
Date Completed: 7-17-02	Litigation		Lexis/Nexis	
Searcher Prep & Review Time: 30	Fulltext		Sequence Systems	
Clerical Prep Time:	Patent Family		WWW/Internet	
Online Time: 47	Other		Other (specify)	

PTO-1590 (8-01)

WHAT IS CLAIMED IS:

1. A method for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy comprising: administering to a patient a composition comprising an effective ~~amount of riboflavin~~, an effector of the urea cycle, and the amino acids alanine, glycine, serine, taurine, threonine and valine.

2. A method according to claim 1 wherein the effector of the urea cycle is arginine, ornithine or citrulline.

3. The method of claim 1 wherein the amino acids are in free form or pharmacologically acceptable salts.

4. The method of claim 1, wherein the concentration of riboflavin is about 5 to about 300 mg/L.

5. The method of claim 1, wherein the concentration of the effector of the urea cycle is about 2 to about 120 mg/L.

6. The method of claim 1, wherein the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

7. The method of claim 1, wherein said composition is administered enterally or parenterally.

8. The method of claim 1, wherein composition is administered intravenously.

9. The method of claim 1, wherein said composition further comprises at least one pharmaceutically-acceptable carrier, diluent, or excipient.

10. The method of claim 1, wherein the composition consists of riboflavin, arginine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable carrier or diluent.

11. The method of claim 10, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of arginine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

12. The method of claim 1, wherein the composition consists of riboflavin, ornithine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable carrier or diluent..

13. The method of claim 12, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of ornithine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

14. A pharmaceutical composition for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy comprising: an effective amount of riboflavin, an effector of the urea cycle, and the amino acids alanine, glycine, serine, taurine, threonine, and valine.

15. The pharmaceutical composition of claim 14, wherein the effector of the urea cycle is selected from arginine, ornithine or citrulline, wherein the effector is in free form or a pharmacologically acceptable salt.

16. The pharmaceutical composition of claim 14 wherein the amino acids are in free form or pharmacologically acceptable salts.

17. The pharmaceutical composition of claim 14, wherein the concentration of riboflavin is about 5 to about 300 mg/L.

18. The pharmaceutical composition of claim 14, wherein the concentration of the effector of the urea cycle is about 2 to about 120 mg/L.

19. The pharmaceutical composition of claim 14, wherein the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

20. The pharmaceutical composition of claim 14, having a pH of about 6.0 to about 7.0.

21. The pharmaceutical composition of claim 14, further comprising at least one pharmaceutically-acceptable carrier, diluent, or excipient.

22. The pharmaceutical composition of claim 14, consisting of riboflavin, arginine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable carrier or diluent.

23. The pharmaceutical composition of claim 22, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of arginine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

24. The pharmaceutical composition of claim 14, consisting of riboflavin, ornithine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable carrier or diluent..

25. The pharmaceutical composition of claim 24, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of ornithine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

26. A method for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy comprising: administering to a patient a composition comprising an effective amount of riboflavin, an effector of the urea cycle comprising arginine and ornithine, and the amino acids alanine, glycine, serine, threonine and valine.

27. The method of claim 26, wherein the composition further comprises 3-phenylacetylamino-2,6-piperidinedione.

28. The method of claim 26, wherein the composition consists of 0.01-10 wt % riboflavin, 1-15 wt % arginine, and 1-15 wt % ornithine, 1-15 wt % alanine, 1-15 wt % glycine, 1-15 wt % serine, 1-15 wt % threonine 1-15 wt % valine, and 25-75 wt % 3-phenylacetylamino-2,6-piperidinedione.

29. A pharmaceutical composition for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy comprising: an effective amount of riboflavin, an effector of the urea cycle comprising arginine and ornithine, and the amino acids alanine, glycine, serine, threonine and valine.

30. The pharmaceutical composition of claim 29, further comprising 3-phenylacetylamino-2,6-piperidinedione.

31. The pharmaceutical composition of claim 29, consisting of 0.01-10 % riboflavin, 1-15 % arginine, and 1-15 wt % ornithine, 1-15 wt % alanine, 1-15 wt % glycine, 1-15 wt % serine, 1-15 wt % threonine 1-15 wt % valine, and 25-75 wt % 3-phenylacetylamino-2,6-piperidinedione.

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Bib Data Sheet

CONFIRMATION NO. 9045

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
09/995,010	11/27/2001 RULE	514	1614	BURG:04910379.0049.NPUS00

APPLICANTS

Stanislaw R. Burzynski, Houston, TX;

** CONTINUING DATA **********

** FOREIGN APPLICATIONS **********

IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** SMALL ENTITY **
** 03/18/2002

		STATE OR COUNTRY	SHEETS DRAWING	TOTAL CLAIMS	INDEPENDENT CLAIMS
Foreign Priority claimed	☐ yes ☐ no	TX		31	4
35 USC 119 (a-d) conditions met	☐ yes ☐ no ☐ Met after Allowance				
Verified and Acknowledged	Examiner's Signature Initials				

ADDRESS

HOWREY SIMON ARNOLD & WHITE
750 Bering Drive
Houston ,TX 77057-2198

TITLE

Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

FILING FEE RECEIVED		
576	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit